These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
103 related articles for article (PubMed ID: 32311470)
1. Squalenoyl-gemcitabine/edelfosine nanoassemblies: Anticancer activity in pediatric cancer cells and pharmacokinetic profile in mice. Rodríguez-Nogales C; Mura S; Couvreur P; Blanco-Prieto MJ Int J Pharm; 2020 May; 582():119345. PubMed ID: 32311470 [TBL] [Abstract][Full Text] [Related]
2. A unique multidrug nanomedicine made of squalenoyl-gemcitabine and alkyl-lysophospholipid edelfosine. Rodríguez-Nogales C; Sebastián V; Irusta S; Desmaële D; Couvreur P; Blanco-Prieto MJ Eur J Pharm Biopharm; 2019 Nov; 144():165-173. PubMed ID: 31546021 [TBL] [Abstract][Full Text] [Related]
3. Decoration of Squalenoyl-Gemcitabine Nanoparticles with Squalenyl-Hydroxybisphosphonate for the Treatment of Bone Tumors. Rodríguez-Nogales C; Desmaële D; Sebastián V; Couvreur P; Blanco-Prieto MJ ChemMedChem; 2021 Dec; 16(24):3730-3738. PubMed ID: 34581019 [TBL] [Abstract][Full Text] [Related]
4. Oral administration of edelfosine encapsulated lipid nanoparticles causes regression of lung metastases in pre-clinical models of osteosarcoma. González-Fernández Y; Brown HK; Patiño-García A; Heymann D; Blanco-Prieto MJ Cancer Lett; 2018 Aug; 430():193-200. PubMed ID: 29802930 [TBL] [Abstract][Full Text] [Related]
5. Combinatorial Nanomedicine Made of Squalenoyl-Gemcitabine and Edelfosine for the Treatment of Osteosarcoma. Rodríguez-Nogales C; Moreno H; Zandueta C; Desmaële D; Lecanda F; Couvreur P; Blanco-Prieto MJ Cancers (Basel); 2020 Jul; 12(7):. PubMed ID: 32674353 [TBL] [Abstract][Full Text] [Related]
6. Gemcitabine-based therapy for pancreatic cancer using the squalenoyl nucleoside monophosphate nanoassemblies. Maksimenko A; Caron J; Mougin J; Desmaële D; Couvreur P Int J Pharm; 2015 Mar; 482(1-2):38-46. PubMed ID: 25448549 [TBL] [Abstract][Full Text] [Related]
7. A new nanomedicine of gemcitabine displays enhanced anticancer activity in sensitive and resistant leukemia types. Reddy LH; Dubernet C; Mouelhi SL; Marque PE; Desmaele D; Couvreur P J Control Release; 2007 Dec; 124(1-2):20-7. PubMed ID: 17878060 [TBL] [Abstract][Full Text] [Related]
8. Doxorubicin and edelfosine lipid nanoparticles are effective acting synergistically against drug-resistant osteosarcoma cancer cells. González-Fernández Y; Imbuluzqueta E; Zalacain M; Mollinedo F; Patiño-García A; Blanco-Prieto MJ Cancer Lett; 2017 Mar; 388():262-268. PubMed ID: 27998763 [TBL] [Abstract][Full Text] [Related]
9. Preferential inactivation of paediatric solid tumour cells by sequential exposure to Merocyanine 540-mediated photodynamic therapy and Edelfosine: implications for the ex vivo purging of autologous haematopoietic stem cell grafts. Anderson GS; Tsujino I; Miyagi K; Sampson R; Sieber F J Photochem Photobiol B; 2003 Feb; 69(2):87-95. PubMed ID: 12633981 [TBL] [Abstract][Full Text] [Related]
10. Preclinical toxicology (subacute and acute) and efficacy of a new squalenoyl gemcitabine anticancer nanomedicine. Reddy LH; Marque PE; Dubernet C; Mouelhi SL; Desmaële D; Couvreur P J Pharmacol Exp Ther; 2008 May; 325(2):484-90. PubMed ID: 18258784 [TBL] [Abstract][Full Text] [Related]
11. Anticancer efficacy of squalenoyl gemcitabine nanomedicine on 60 human tumor cell panel and on experimental tumor. Reddy LH; Renoir JM; Marsaud V; Lepetre-Mouelhi S; Desmaële D; Couvreur P Mol Pharm; 2009; 6(5):1526-35. PubMed ID: 19634915 [TBL] [Abstract][Full Text] [Related]
12. Interaction of an amphiphilic squalenoyl prodrug of gemcitabine with cellular membranes. Bildstein L; Pili B; Marsaud V; Wack S; Meneau F; Lepêtre-Mouelhi S; Desmaële D; Bourgaux C; Couvreur P; Dubernet C Eur J Pharm Biopharm; 2011 Nov; 79(3):612-20. PubMed ID: 21784150 [TBL] [Abstract][Full Text] [Related]
14. Squalenoyl nanomedicine of gemcitabine is more potent after oral administration in leukemia-bearing rats: study of mechanisms. Reddy LH; Ferreira H; Dubernet C; Mouelhi SL; Desmaele D; Rousseau B; Couvreur P Anticancer Drugs; 2008 Nov; 19(10):999-1006. PubMed ID: 18827565 [TBL] [Abstract][Full Text] [Related]
15. Interfacial behavior of PEGylated lipids and their effect on the stability of squalenoyl-drug nanoassemblies. Bekkara-Aounallah F; Ambike A; Gref R; Couvreur P; Rosilio V Int J Pharm; 2014 Aug; 471(1-2):75-82. PubMed ID: 24811925 [TBL] [Abstract][Full Text] [Related]
16. Transmembrane diffusion of gemcitabine by a nanoparticulate squalenoyl prodrug: an original drug delivery pathway. Bildstein L; Dubernet C; Marsaud V; Chacun H; Nicolas V; Gueutin C; Sarasin A; Bénech H; Lepêtre-Mouelhi S; Desmaële D; Couvreur P J Control Release; 2010 Oct; 147(2):163-70. PubMed ID: 20691740 [TBL] [Abstract][Full Text] [Related]
17. PEGylated squalenoyl-gemcitabine nanoparticles for the treatment of glioblastoma. Gaudin A; Song E; King AR; Saucier-Sawyer JK; Bindra R; Desmaële D; Couvreur P; Saltzman WM Biomaterials; 2016 Oct; 105():136-144. PubMed ID: 27521616 [TBL] [Abstract][Full Text] [Related]
18. Improving the antitumor activity of squalenoyl-paclitaxel conjugate nanoassemblies by manipulating the linker between paclitaxel and squalene. Caron J; Maksimenko A; Wack S; Lepeltier E; Bourgaux C; Morvan E; Leblanc K; Couvreur P; Desmaële D Adv Healthc Mater; 2013 Jan; 2(1):172-85. PubMed ID: 23213041 [TBL] [Abstract][Full Text] [Related]
19. Edelfosine nanoemulsions inhibit tumor growth of triple negative breast cancer in zebrafish xenograft model. Saraiva SM; Gutiérrez-Lovera C; Martínez-Val J; Lores S; Bouzo BL; Díez-Villares S; Alijas S; Pensado-López A; Vázquez-Ríos AJ; Sánchez L; de la Fuente M Sci Rep; 2021 May; 11(1):9873. PubMed ID: 33972572 [TBL] [Abstract][Full Text] [Related]